0001764013-23-000153.txt : 20231205 0001764013-23-000153.hdr.sgml : 20231205 20231205162533 ACCESSION NUMBER: 0001764013-23-000153 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231201 FILED AS OF DATE: 20231205 DATE AS OF CHANGE: 20231205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MIGAUSKY GEORGE V CENTRAL INDEX KEY: 0001134365 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38906 FILM NUMBER: 231466937 MAIL ADDRESS: STREET 1: C/O DYAX CORP. STREET 2: 300 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Immunovant, Inc. CENTRAL INDEX KEY: 0001764013 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 832771572 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: 917-580-3099 MAIL ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Health Sciences Acquisitions Corp DATE OF NAME CHANGE: 20190108 4 1 wk-form4_1701811523.xml FORM 4 X0508 4 2023-12-01 0 0001764013 Immunovant, Inc. IMVT 0001134365 MIGAUSKY GEORGE V 320 W 37TH STREET, 6TH FLOOR NEW YORK NY 10018 1 0 0 0 1 Common Stock 2023-12-01 4 S 0 4200 38.79 D 118308 D Common Stock 2023-12-01 4 S 0 3478 39.81 D 114830 D Common Stock 2023-12-01 4 S 0 5022 40.46 D 109808 D Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.20 - $39.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.20 - $40.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.20 - $40.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. /s/ Eva Renee Barnett, attorney-in-fact for George V. Migausky 2023-12-05